Clinical trial
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor…
NCT00281983 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00281983 |
|---|---|
| Title | Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia |
| Official title | Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia |
| Lead sponsor | German CLL Study Group, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | alemtuzumab, anti-thymocyte globulin, filgrastim, rituximab, therapeutic allogeneic lymphocytes, busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate and 3 more |
| Enrollment | 100 |
| Start date | Jun 1, 2000 |
| Completion | Jul 1, 2010 |
| First posted | Jan 25, 2006 |
| Last update posted | Jul 24, 2017 |
| Countries | Canada, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: